| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $89,373,614 | +$26,797,898 | 10,353,875 | +43% | Fairmount Funds Management LLC | 06 Oct 2025 |
| FMR LLC | 15% | $40,965,976 | 4,735,951 | FMR LLC | 30 May 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 3,220,369 | Venrock Healthcare Capital Partners III, L.P. | 28 Apr 2025 | ||||
| RA CAPITAL MANAGEMENT, L.P. | 7% | +72% | $27,758,685 | +$16,318,768 | 3,214,969 | +143% | RA Capital Management, L.P. | 08 Oct 2025 |
| Deep Track Capital, LP | 7% | -18% | $19,675,468 | -$4,356,044 | 2,279,892 | -18% | Deep Track Capital, LP | 30 Sep 2025 |
| BlackRock, Inc. | 6.6% | +26% | $18,565,283 | +$3,763,346 | 2,150,203 | +25% | BlackRock, Inc. | 30 Sep 2025 |
| VANGUARD GROUP INC | 5.6% | $15,635,584 | 1,807,582 | The Vanguard Group | 30 Jun 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | 0% | $11,949,495 | +$379,228 | 1,384,646 | +3.3% | Frazier Life Sciences Public Fund, L.P. | 30 Sep 2025 |
| TCG Crossover GP I, LLC | 0.2% | 64,023 | TCG Crossover GP I, LLC | 28 Apr 2025 | ||||
| Atlas Venture Fund XII, L.P. | 0.2% | 51,406 | Atlas Venture Associates XII, L.P. | 28 Apr 2025 |
As of 30 Sep 2025, 74 institutional investors reported holding 31,617,300 shares of Jade Biosciences, Inc. - Common Stock, $0.0001 par value per share (JBIO). This represents 96% of the company’s total 32,967,762 outstanding shares.
The largest institutional shareholders of Jade Biosciences, Inc. - Common Stock, $0.0001 par value per share (JBIO) together control 94% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 4,888,781 | +1.1% | 0% | $42,190,180 |
| Fairmount Funds Management LLC | 9.8% | 3,220,368 | 0% | 2.5% | $27,791,776 |
| VR ADVISER, LLC | 9.8% | 3,220,364 | 0% | 1.6% | $27,791,741 |
| Deep Track Capital, LP | 6.9% | 2,279,892 | -9.1% | 0.55% | $19,675,468 |
| BlackRock, Inc. | 6.5% | 2,150,203 | +25% | 0% | $18,556,252 |
| VANGUARD GROUP INC | 5.2% | 1,726,744 | -4.5% | 0% | $14,901,801 |
| Versant Venture Management, LLC | 4.6% | 1,525,820 | 0% | 6.2% | $13,167,827 |
| RTW INVESTMENTS, LP | 4.4% | 1,449,273 | 0% | 0.15% | $12,507,226 |
| Frazier Life Sciences Management, L.P. | 4.3% | 1,413,280 | -20% | 0.37% | $12,196,606 |
| Driehaus Capital Management LLC | 3.8% | 1,255,798 | 0% | 0.08% | $10,837,537 |
| Avidity Partners Management LP | 3.4% | 1,127,186 | 0% | 2.2% | $9,727,615 |
| RA CAPITAL MANAGEMENT, L.P. | 3.2% | 1,062,326 | 0% | 0.11% | $9,167,873 |
| Soleus Capital Management, L.P. | 2.4% | 796,744 | 0% | 0.37% | $6,875,901 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 665,915 | -1.6% | 0% | $5,748,163 |
| GREAT POINT PARTNERS LLC | 1.9% | 632,599 | +27% | 2.3% | $5,459,329 |
| Logos Global Management LP | 1.9% | 625,000 | 0% | 0.53% | $5,393,750 |
| SAMSARA BIOCAPITAL, LLC | 1.6% | 531,163 | 0% | 0.6% | $4,583,937 |
| ORBIMED ADVISORS LLC | 1.6% | 531,163 | 0% | 0.11% | $4,583,937 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.6% | 531,163 | 0% | 0.07% | $4,583,937 |
| STATE STREET CORP | 1.5% | 499,287 | +57% | 0% | $4,308,847 |
| NORTHERN TRUST CORP | 0.7% | 229,581 | +0.65% | 0% | $1,981,284 |
| GOLDMAN SACHS GROUP INC | 0.49% | 162,711 | 0% | $1,404,196 | |
| WELLINGTON MANAGEMENT GROUP LLP | 0.33% | 107,553 | 0% | $928,182 | |
| Sofinnova Investments, Inc. | 0.33% | 107,391 | 0% | 0.06% | $926,784 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.28% | 93,250 | -9.7% | 0% | $804,748 |